CGC Stock Analysis: Buy, Sell, or Hold?
CGC - Canopy Growth Corporation Common Shares
$0.96
0.04 (4.40%)
▲
5d:
+3.61%
30d:
-4.23%
90d:
-15.25%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 07, 2026
3d
Get Alerted When CGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGC shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CGC shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGC is currently trading at $0.96, which is considered slightly high relative to its 30-day fair value range of $0.91 to $0.97. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.6) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CGC is in a downtrend. The price is approaching resistance at $0.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.24 (+35.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGC is in a downtrend. The price is approaching resistance at $0.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.24 (+35.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.91 -
$0.97
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 35.0% below Wall St target ($1.24)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.91 -
$0.97
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.86
Resistance Level
$0.96
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.58
Wall Street Target
$1.24
(+35.0%)
Revenue Growth (YoY)
9.6%
Profit Margin
-92.4%
PE vs Historical
-3.6 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: August 03, 2026 4:06 PM ET
Data refreshes hourly during market hours. Next update: 5:06 PM
Data refreshes hourly during market hours. Next update: 5:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Bayern
SELL
2658 shares
2026-03-31
M Shan Atkins
SELL
2074 shares
2026-03-31
Theresa Yanofsky
SELL
10373 shares
2026-03-31
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced CGC Option Strategies
Professional options setups generated by AI based on today's CGC price and gamma walls.
